Press release summary
Sysmex and Hologen have formed Saibogen, a joint venture that plans to apply generative artificial intelligence to detailed data produced by routine hematology analyzers. Announced Nov. 9, the company will combine Hologen’s Large Medicine Models with proprietary data from Sysmex systems to search for biological signals beyond the standard parameters reported in a complete blood count.
The companies said the approach is intended to work with tests laboratories already perform, without requiring new instruments, reagents or patient samples. Sysmex analyzers process about 3 billion tests annually, according to the release, giving the venture access to a large body of standardized hematology data. Saibogen plans to make resulting insights available to health care and clinical-research partners, though the announcement did not provide a commercial rollout timetable or regulatory pathway.
Why it matters to laboratory readers
The venture reflects a broader shift from instrument-only innovation toward software that extracts additional value from existing laboratory data. If the models are validated, laboratories could gain new research or decision-support capabilities without replacing analyzers. Adoption would still depend on evidence for clinical performance, generalizability and bias, as well as clear controls for data governance, LIS integration and regulatory oversight.
Read the original Nov. 9 announcement from Saibogen via GlobeNewswire.
Leave a Reply